Intec Pharma

Tel Aviv Stock Exchange: NTEC

NIS495.1m market cap

NIS14.9 last close

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson’s in Phase III and AP-ZP for insomnia in Phase II.

Investment summary

Edison Investment Research is terminating coverage on Intec Pharma (NTEC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2016A 0.0 (14.5) (13.4) (116.72) N/A N/A
2017A 0.0 (30.1) (29.1) (164.74) N/A N/A
2018E 0.0 (31.2) (29.5) (93.22) N/A N/A
2019E 0.0 (25.0) (22.8) (67.94) N/A N/A
Share price graph
Balance sheet
Forecast net cash (US$m) 57.2
Forecast gearing ratio (%) N/A
Price performance
Actual 0.0 (10.4) (47.9)
Relative* 4.7 (12.9) (52.4)
52-week high/low NIS29.6/NIS14.3
*% relative to local index
Key management
John W Kozarich Chairman
Jeffrey A Meckler CEO
Nir Sassi CFO